These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 10372270)

  • 41. Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article.
    Rolny P; Vatn M
    Scand J Gastroenterol; 2013 Feb; 48(2):131-5. PubMed ID: 23110487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
    Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Refractory IBD: medical management.
    Tremaine WJ
    Neth J Med; 1997 Feb; 50(2):S12-4. PubMed ID: 9050327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
    Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topical delivery of steroids in inflammatory bowel disease.
    Girlich C; Scholmerich J
    Curr Drug Deliv; 2012 Jul; 9(4):345-9. PubMed ID: 22762277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of inflammatory bowel disease in adults.
    Katz JA
    J Dig Dis; 2007 May; 8(2):65-71. PubMed ID: 17532817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimizing therapy for inflammatory bowel disease.
    Robinson M
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Recurrence-preventive (remission preserving) therapy of chronic inflammatory bowel diseases].
    Kruis W; Pohl C
    Dtsch Med Wochenschr; 1998 Jan; 123(4):85-7. PubMed ID: 9487288
    [No Abstract]   [Full Text] [Related]  

  • 51. A practical guide to the management of distal ulcerative colitis.
    Ardizzone S; Bianchi Porro G
    Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New treatments in inflammatory bowel disease.
    Cole AT; Hawkey CJ
    Br J Hosp Med; 1992 Apr 15-May 5; 47(8):581-90. PubMed ID: 1591558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclosporine A for induction of remission in severe ulcerative colitis.
    Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease.
    Müller KE; Lakatos PL; Arató A; Kovács JB; Várkonyi Á; Szűcs D; Szakos E; Sólyom E; Kovács M; Polgár M; Nemes É; Guthy I; Tokodi I; Tóth G; Horváth Á; Tárnok A; Csoszánszki N; Balogh M; Vass N; Bódi P; Dezsőfi A; Gárdos L; Micskey E; Papp M; Cseh Á; Szabó D; Vörös P; Veres G;
    J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):576-82. PubMed ID: 23820399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study.
    Blumenstein I; Bock H; Weber C; Rambow A; Tacke W; Kihn R; Pfaff R; Orlemann S; Schaeffer R; Schröder O; Dignass A; Hartmann F; Stein J
    Inflamm Bowel Dis; 2008 Jan; 14(1):53-60. PubMed ID: 17973301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.
    Protic M; Seibold F; Schoepfer A; Radojicic Z; Juillerat P; Bojic D; Mwinyi J; Mottet C; Jojic N; Beglinger C; Vavricka S; Rogler G; Frei P
    J Crohns Colitis; 2014 Nov; 8(11):1427-37. PubMed ID: 24908178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
    Ochsenkühn T; Sackmann M; Göke B
    Radiologe; 2003 Jan; 43(1):1-8. PubMed ID: 12552369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conventional medical management of inflammatory bowel disease.
    Burger D; Travis S
    Gastroenterology; 2011 May; 140(6):1827-1837.e2. PubMed ID: 21530749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How important is onset of action in ulcerative colitis therapy?
    Masson S; Nylander D; Mansfield JC
    Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.